Fullerenes in targeted therapies
View Patent ↗Herein we disclose a composition, comprising a C n -Ab, wherein C n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is linked to the Cn. The composition can further comprise a therapeutic molecule associated with the C n -Ab. Also, we disclose a method of treating a disease in a mammal, comprising administering to the mammal an effective amount of the composition.
1. A composition, comprising:
(i) a C n -Ab, wherein C n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is covalently linked to the C n , wherein the antigen-binding site recognizes an antigen associated with a medical condition; and (ii) a pharmaceutically-acceptable carrier.
2. The composition of claim 1 , wherein the C n is substituted with one or more water-solubilizing groups.
3. The composition of claim 1 , wherein the Ab comprises an antigen-binding site selected from ZME-018, SCFVMEL, dSCFVMEL, GD2, HuM195, herceptin, BACH 250, ML 3-9, C 6.5, or αMMP9.
4. The composition of claim 1 , further comprising a therapeutic molecule associated with the C n -Ab.
5. The composition of claim 4 , wherein the therapeutic molecule is covalently bound to the C n .
6. The composition of claim 4 , wherein the C n is substituted with a polar group and the therapeutic molecule is associated with the polar group.
7. The composition of claim 4 , wherein the therapeutic molecule is paclitaxel, doxorubicin, vincristine, or cisplatin.
8. A method of treating a disease in a mammal, comprising:
administering to the mammal an effective amount of a composition comprising (i) a C n -Ab, wherein C n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is covalently linked to the C n , wherein the antigen-binding site recognizes an antigen associated with the disease, and (ii) a pharmaceutically-acceptable carrier.
9. The method of claim 8 , the C n is substituted with one or more water-solubilizing groups.
10. The method of claim 8 , wherein the Ab comprises an antigen-binding site selected from ZME-018, SCFVMEL, dSCFVMEL, GD2, HuM195, herceptin, BACH 250, ML 3-9, C 6.5, or αMMP9.
11. The method of claim 8 , wherein the disease is an oxidative stress disease.
12. The method of claim 8 , wherein the composition is administered at a dosage of from about 0.001 mg C n per kg body weight per day to about 1 g C n per kg body weight per day.
13. The method of claim 8 , wherein the composition further comprises a therapeutic molecule associated with the C n -Ab.
14. The method of claim 13 , wherein the therapeutic molecule is paclitaxel, doxorubicin, vincristine, or cisplatin.
15. The method of claim 13 , wherein the composition is administered at a dosage of from about 0.001 mg therapeutic molecule per kg body weight per day to about 1 g therapeutic molecule per kg body weight per day.
16. The method of claim 8 , wherein the method further comprises administering an adjuvant to the mammal, wherein the adjuvant dissociates the therapeutic molecule from the C n -Ab.